Gagnon Hugo, Paré Marie-Frédérique, Costaguta Guillermo, Turcotte Marie-Catherine, Jantchou Prévost, Chapuy Laurence, Deslandres Colette
Centre Hospitalier Universitaire Sainte-Justine, Division of Gastroenterology, Hepatology and Nutrition Montréal Quebec Canada.
Centre de Recherche du CHU Sainte-Justine Université de Montréal Montréal Quebec Canada.
JPGN Rep. 2025 Jun 24;6(3):219-226. doi: 10.1002/jpr3.70052. eCollection 2025 Aug.
Despite biological treatments reducing the burden of pediatric inflammatory bowel disease, many patients still require surgery. Data on pediatric patient characteristics and surgical incidence are limited, often based on adult studies. This study aimed to assess the characteristics of pediatric Crohn's disease (CD) at diagnosis and compare surgery rates between two periods (before and after 2019) to understand which patients require surgery.
We analyzed pediatric CD patients who underwent surgery at CHU Sainte-Justine, Montreal, between 2014 and 2023. Descriptive statistics and the Mann-Whitney -test were used to compare means, while Kaplan-Meier curves assessed surgery-free survival, with significance set at < 0.05.
The overall surgery incidence was 5.2/1000 person-years. Surgery rates were lower for patients diagnosed after 2019 than before 2019 (5.6/1000 vs. 14.7/1000 person-years). There were no significant differences in age at diagnosis, CD Paris score, reason for surgery, or disease severity. Among CD patients, surgeries were more frequent before 2019 (11.5% vs. 2.8%, < 0.001). The reduction in surgery rates since 2019 is likely due to earlier initiation of biologics, with a median initiation of 14 days after 2019 compared to 142 days before 2019 ( = 0.01).
The reduced incidence of surgery in pediatric CD is a significant achievement. Increased use of infliximab, proactive drug monitoring, and better nonresponder management likely contribute to this improvement.
尽管生物治疗减轻了儿童炎症性肠病的负担,但许多患者仍需要手术。关于儿科患者特征和手术发生率的数据有限,且往往基于成人研究。本研究旨在评估儿童克罗恩病(CD)诊断时的特征,并比较两个时期(2019年之前和之后)的手术率,以了解哪些患者需要手术。
我们分析了2014年至2023年期间在蒙特利尔圣贾斯汀大学医学中心接受手术的儿科CD患者。使用描述性统计和曼-惠特尼检验来比较均值,同时采用Kaplan-Meier曲线评估无手术生存期,显著性设定为<0.05。
总体手术发生率为5.2/1000人年。2019年之后诊断的患者手术率低于2019年之前(5.6/1000对14.7/1000人年)。诊断时的年龄、CD巴黎评分、手术原因或疾病严重程度方面无显著差异。在CD患者中,2019年之前手术更为频繁(11.5%对2.8%,<0.001)。自2019年以来手术率的降低可能是由于生物制剂更早开始使用,2019年之后的中位开始时间为14天,而2019年之前为142天(P = 0.01)。
儿科CD手术发生率的降低是一项重大成就。英夫利昔单抗使用增加、积极的药物监测以及更好的无反应者管理可能促成了这一改善。